Ovid Therapeutics (OVID) Capital Expenditures Growth (3y) (2019 - 2024)
Powered by 
Analysis
Ovid Therapeutics (OVID) Capital Expenditures Growth (3y) (2019 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 5.53% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 21.85% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -2.55% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -12.57% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -16.45% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | -40.95% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 19.16% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -29.28% |
| Jun 30, 2024 | 4,494.70% |
| Mar 31, 2024 | 18.17% |
| Dec 31, 2023 | -31.38% |
| Jun 30, 2023 | 217.48% |
| Mar 31, 2023 | -57.99% |
| Dec 31, 2022 | -9.34% |
| Sep 30, 2022 | 0.71% |
| Jun 30, 2022 | 598.60% |
| Mar 31, 2022 | 114.57% |
| Dec 31, 2021 | 81.58% |
| Sep 30, 2021 | -55.22% |
| Jun 30, 2021 | -98.00% |
| Mar 31, 2021 | -38.52% |
| Dec 31, 2020 | 48.03% |
| Sep 30, 2020 | 12.34% |
| Jun 30, 2020 | -47.99% |
| Mar 31, 2020 | 67.15% |
| Dec 31, 2019 | 23.89% |
| Sep 30, 2019 | -29.52% |